BIIB241011P197500
- 13.80
- +6.73+95.19%
Biogen Newsroom
Morgan Stanley's List of Tax Loss Selling Stocks
Biogen Stock Touches 52-week Low at $183.55 Amid Market Challenges
Scholar Rock Stock Quadruples on Positive Trial Data -- Barrons.com
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term
Barclays Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $190
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Biogen (BIIB)
RBC Cuts Price Target on Biogen to $269 From $292, Keeps Outperform Rating
Biogen Is Maintained at Neutral by UBS
Biogen Analyst Ratings
Larimar Started at Outperform by Wedbush on FA Drug Candidate
Looking Into Biogen's Recent Short Interest
UBS Sees More Downside and Than Upside in Biogen Stock
UBS Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $202
Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
The Past Three Years for Biogen (NASDAQ:BIIB) Investors Has Not Been Profitable
Biogen to Report Third Quarter 2024 Financial Results October 30, 2024
Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal